Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This review found that adding α1-blockers to 5α-reductase inhibitors may improve lower urinary tract symptoms in men with non-neurogenic conditions, based on existing evidence.

Minoxidil reacts to nitrosation 7 times more than phenol, mainly due to its -NH₂ groups, leading to the creation of N-nitrosominoxidil.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

Minoxidil effectively lowers blood pressure and initially increases plasma renin activity without raising aldosterone levels.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

Minoxidil lowers blood pressure and increases heart efficiency, but may raise lung artery pressure in some people.

This review explores the molecular mechanisms and potential roles of nitric oxide in COVID-19 therapy, but provides no new clinical results.

This study found that minoxidil effectively manages various types of severe hypertension but can cause side effects such as sodium retention and tachycardia.

This study found that cromakalim and pinacidil significantly inhibited porcine detrusor muscle contractions, suggesting these ATP-sensitive potassium channel openers may have potential in treating certain bladder diseases.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

In this study, the pharmacological action of dobutamine on rabbit retinae was found to be distinct from that of other dopamine analogs like apomorphine and N-methyl-dopamine.

This article describes the synthesis of novel polyamine-modified minoxidil analogs and conjugates to potentially enhance minoxidil's biological activity, selectivity, and water solubility, but reports no new biological results.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

This study identified a sulfotransferase activity in rat liver that catalyzes the sulfation of minoxidil, contributing to its delayed hypotensive effects.

This update provides information on new drug approvals but does not offer new clinical research findings.

Propranolol affects heart rate and renin levels in minoxidil-treated patients.

In this study, minoxidil effectively reduced blood pressure to near normal levels in patients with malignant or accelerated hypertension resistant to conventional treatments, offering a potential alternative to nephrectomy.

In this case study, treatment with methylene blue successfully improved blood pressure in a patient with refractory vasodilatory shock due to massive minoxidil ingestion, highlighting its potential as an adjunctive therapy.

Minoxidil given intravenously caused small changes in diastolic blood pressure and increased heart rate at higher concentrations in patients with high blood pressure.

This review discusses the effectiveness and tolerability of alpha1-adrenoceptor antagonists for managing lower urinary tract symptoms in benign prostatic hyperplasia, reporting no new clinical results.

This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.

This study found that minoxidil significantly reduces systemic blood pressure and vascular resistance in patients with hypertension, but does not alter pulmonary vascular resistance or exacerbate pulmonary hypertension.